Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03034772 | Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration | PHASE2 | COMPLETED | 52 | — | — | Feb 8, 2017 | Jul 5, 2019 | Jun 19, 2020 | 5 | United States |
Change in mean CST on spectral domain optical coherence tomography from baseline to the final visit
| Arm | Type | Description |
|---|---|---|
| Dorzolamide-timolol | ACTIVE_COMPARATOR | Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals. |
| Artificial tears | PLACEBO_COMPARATOR | Topical artificial tears twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals. |
| Name | Type | Description |
|---|---|---|
| Dorzolamide-timolol | DRUG | Topical eye drop (active comparator) used twice daily for study duration |
| Artificial tears | OTHER | Topical eye drop (placebo comparator) used twice daily for study duration |
Inclusion Criteria: 1. Active choroidal neovascularization (CNV) due to AMD. 2. Prior treatment with at least 4 injections of anti-VEGF agents in the past 6 months and persistent intraretinal and/or subretinal fluid on SD-OCT at each visit during this period. 3. Baseline CST ≥ 270 µm on SD-OCT auto...